Hydroxychloroquine Sulfate Actavis

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Hydroxychloroquine Sulfate Actavis

Property Description
Active ingredient Hydroxychloroquine
Form Film-coated tablets
Pharmacological class Antimalarial, Disease-Modifying Antirheumatic Drug (DMARD)
General Role Immunomodulation, Anti-inflammatory effect
Origin Synthetic compound (4-aminoquinoline derivative)

Hydroxychloroquine Sulfate Actavis is a prescription-only, single-ingredient product supplied by Actavis. It is a synthetic 4-aminoquinoline derivative officially classified as both an Antimalarial agent and a Disease-Modifying Antirheumatic Drug (DMARD), establishing its role in addressing infectious processes and chronic conditions characterized by systemic inflammation.


What Type of Medicine is Hydroxychloroquine Sulfate?

Hydroxychloroquine sulfate is a therapeutic agent that belongs to the pharmacological classes of antimalarials and antirheumatics. The active substance, Hydroxychloroquine, is a synthetic analogue of the older compound chloroquine. This chemical structure features a hydroxyl group modification, which distinguishes its pharmacological profile. This classification means the medicine is designed for the sustained, systemic adjustment of the immune system.


Composition and General Purpose

The Hydroxychloroquine Sulfate Actavis preparation is a monotherapy formulation supplied as film-coated tablets for oral administration. Containing only Hydroxychloroquine sulfate as its active ingredient, the medicine is absorbed systemically to exert its primary functions throughout the body.

The general role of the medicine is achieved through immunomodulation and a resulting anti-inflammatory effect. Its mechanism involves altering the internal environment of certain immune cells, which is clinically recognized for helping to mitigate the unwanted progression of systemic immune responses. This core function allows the medicine to sustain control over chronic inflammation, making it a common choice for initial therapeutic regimens where persistent immune overactivity is a primary concern.

Advertisements

What side effects are possible with Hydroxychloroquine Sulfate Actavis?

Possible Side Effects and Safety Information

The safety profile of Hydroxychloroquine Sulfate is defined by officially documented adverse reactions categorized by frequency and the physiological systems affected, based on regulatory labeling.


Frequency-Classified Adverse Reactions

The most frequently reported effects typically involve the gastrointestinal and integumentary systems. Reactions are categorized as follows:

  • Common (ge 1/100 to < 1/10): Nausea, Diarrhea, Abdominal Cramps, Rash, and Pruritus (itching).
  • Uncommon (ge 1/1,000 to < 1/100): Alopecia (hair loss) and changes in skin pigmentation.
  • Rare (ge 1/10,000 to < 1/1,000): Include Retinopathy, Cardiomyopathy, and Severe Hypoglycemia.

Serious Adverse Reactions and Safety Constraints

Official labeling highlights the risk of several serious adverse reactions, which define critical limitations for use. The most significant long-term concern is Irreversible Retinal Damage (Retinopathy/Maculopathy). This risk is explicitly documented as dose- and duration-dependent, primarily associated with prolonged exposure.

Serious, less common adverse reactions documented include:

  • Cardiac Events: Cardiomyopathy, QTc prolongation, and Ventricular Arrhythmias.
  • Hematological Effects: Bone marrow suppression, such as Agranulocytosis and Aplastic Anemia.

Safety constraints include Contraindications against use in individuals with pre-existing known maculopathy of the eye or hypersensitivity to 4-aminoquinoline derivatives. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency are noted to have an increased risk of hemolysis.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Acute overdose of Hydroxychloroquine Sulfate is considered a life-threatening medical emergency requiring immediate professional intervention due to the risk of severe and rapidly progressing toxicity.

Feature Official Regulatory Statements (Strictly Overdose Context)
Documented Overdose Presentations Profound cardiac toxicity, including QRS widening, QT prolongation, ventricular arrhythmias, and hypotension. Central nervous system effects include seizures, decreased consciousness, and progression to coma. Acute hypokalemia (low blood potassium) is also a documented physiological finding.
Severe Outcomes Cardiac arrest and death are listed as potential severe outcomes. Loss of vision may also be permanent.
Emergency-Response Seek immediate medical attention and call emergency services (911) or a Poison Control Center immediately for any suspected overdose. Hospitalization, with continuous cardiac monitoring (ECG/EKG), is required for stabilization.
Population-Specific Risk Ingestion of even a small number of tablets (one to two) has been reported as potentially fatal in children under six years old.

No specific antidote is known for this overdose; therefore, management described in regulatory documents is purely symptomatic and supportive, focusing on continuous monitoring and the use of supportive measures like activated charcoal and specific agents to manage hypokalemia and seizures.

Advertisements

Therapeutic Uses of Hydroxychloroquine Sulfate Actavis

What Hydroxychloroquine Sulfate Actavis Treats: Main Uses and Benefits

This medicine is classified as a disease-modifying anti-rheumatic drug (DMARD) and is applied across domains where additional symptomatic support is needed in conditions involving inflammatory or irritative states.

Support for Systemic Conditions and Symptom Clusters

This medicine is commonly used for managing conditions characterized by periods of heightened symptoms, such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Malaria. It plays a role in managing systemic imbalance, and is considered relevant for supporting the body during periods of heightened symptoms. It is also relevant for easing symptom clusters related to physical discomfort, such as joint pain, swelling, and stiffness.

The use is generally aligned with scenarios where short-term symptomatic assistance is needed or where long-term symptomatic support is appropriate. This supports patients during episodes of heightened discomfort and assists with maintaining functional stability.

Quick Fact: Symptomatic Support for Joints and Skin
This medicine is relevant for easing symptoms related to inflammatory or irritative states, including noticeable physical discomfort in the joints and the distinctive skin rashes associated with Lupus. This provides supportive relief when symptoms interfere with routine activities.
Advertisements

Eligibility and Restrictions for Use

Hydroxychloroquine Sulfate is generally eligible for adults and pediatric patients for its approved uses, subject to strict regulatory conditions and absolute contraindications. The official label establishes clear rules on who is prohibited from using the medicine and who requires restricted use.

Populations for Whom Use is Contraindicated

Use is absolutely contraindicated in patients with a known hypersensitivity to any 4-aminoquinoline compound (such as chloroquine) or to any component of the formulation. It is also prohibited for patients with pre-existing maculopathy or other serious retinal changes of the eye, as the medicine can cause irreversible damage. Some international labels contraindicate use in children below 6 years of age.

Condition-Specific Eligibility Restrictions

Use requires caution and close monitoring in patients with hepatic impairment or renal impairment, as the medicine is processed by the liver and excreted by the kidneys. Caution is also advised for those with a history of psoriasis or porphyria, as the medicine may exacerbate these conditions. Use is also restricted in patients with cardiac conduction disorders or other risk factors for QT prolongation.

Age and Physiological Status

For pediatric patients, the 200 mg tablet form is not recommended for those weighing less than 31 kg for rheumatological conditions, due to the difficulty in safe, accurate weight-based dosing. Regarding pregnancy, the medicine should be used only if the benefit outweighs the potential risk to the fetus. It is generally not recommended during lactation.

Advertisements

What should I know about interactions with other medicines?

Hydroxychloroquine Sulfate Actavis Interactions with other medicines and products

This section details officially documented interactions between Hydroxychloroquine Sulfate Actavis and other medicinal products, based on government regulatory information.

Formal Interaction Restrictions

Co-administration is officially restricted with medicinal products that have the potential to prolong the QT interval. This constraint is necessary due to the documented risk of additive cardiotoxicity, including ventricular arrhythmias.

Clinically Significant Co-administration Cautions

Specific monitoring or constraint is required when co-administering the following agents:

  • Antidiabetic Agents and Insulin: Co-administration carries an officially documented risk of severe hypoglycemia.
  • Tamoxifen: Concomitant use increases the risk of irreversible retinal damage.
  • Mefloquine: Use with Mefloquine is associated with an increased risk of convulsions or seizures.

Interactions Affecting Drug Exposure

Interacting Agent Official Effect on Drug Levels
Digoxin Hydroxychloroquine increases serum Digoxin levels.
Ciclosporin (Cyclosporine) Hydroxychloroquine increases plasma Ciclosporin levels.
Cimetidine Increases plasma levels of Hydroxychloroquine.
Antacids Reduce Hydroxychloroquine absorption.

Timing Separation and Population Notes

Antacids must be administered at least 4 hours apart from Hydroxychloroquine Sulfate to prevent reduced drug absorption. Patients with underlying hepatic or renal disease are noted in the regulatory label as requiring cautious monitoring due to the potential for reduced drug clearance.

Advertisements

Mechanism of Action

Modulating Intracellular Signaling via pH

The drug functions as a weak base, leading to its accumulation and subsequent pH increase (alkalinization) within acidic compartments, primarily endosomes and lysosomes, inside immune cells. This pH shift functionally inhibits pH-dependent proteins, specifically blocking the signaling initiated by endosomal Toll-like Receptors (TLR-7 and TLR-9). This interference modifies molecular steps that regulate immune responses, resulting in a reduction in the release of pro-inflammatory messengers such as Interferon-alpha (IFN-alpha ) and Interleukin-6 (IL-6).

Modifying Adaptive Immune Responses

The same pH modulation disrupts the ability of Antigen-Presenting Cells (APCs) to process and display antigens via MHC-II molecules. By impairing this upstream activation signal, the drug restricts the full activation of T-cells. This promotes a modulated state within the adaptive immune pathway, which contributes to modifying the physiological consequences of excessive mediator activity.

Mechanism-Dependent Time Constraint

Effective modulation hinges on the drug's slow, steady accumulation and trapping within specific target tissues and intracellular vesicles. This necessary process means the resulting modulation of physiological activity is intrinsically delayed, requiring sustained use over weeks to months before the necessary modulation of immune activity is achieved.

Advertisements

Dosage and Administration Information

Official Administration Guidelines

Hydroxychloroquine Sulfate Actavis is supplied as film-coated tablets for oral administration only. The official use of this medicine is defined by strict dose ceilings and specific instructions regarding frequency and intake conditions, all detailed in regulatory documents.

Usage Domain Official Instructions as per Regulatory Label
Route & Intake Must be administered orally with a meal or a glass of milk.
Tablet Integrity Tablets must be swallowed whole; they should not be crushed or divided.
Chronic Dose Ceiling The chronic daily dose should not exceed 6.5 mg/kg of ideal body weight for long-term use.
RA / Lupus Dosing Standard maintenance dose ranges from 200 mg to 400 mg daily, taken as a single dose or two divided doses.
Malaria Dosing Prophylaxis: 400 mg once weekly, continued for 4 weeks after leaving the endemic area. Acute Treatment: An initial dose of 800 mg is followed by 400 mg at 6, 24, and 48 hours.
Use Duration For chronic conditions, treatment should be discontinued if no improvement is observed after 6 months.

Age-Specific Rules

Official dosing for pediatric patients is calculated based on body weight. The 200 mg tablet strength is not recommended for children weighing less than 31 kg because the lowest available dose would exceed the weight-based guidelines.

Missed Dose Instruction

If a dose is missed, it should be taken as soon as remembered, unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. Two doses should never be taken at the same time to compensate for a missed dose.


Advertisements

Recent Clinical Evidence

Hydroxychloroquine Sulfate Actavis: Recent Clinical Evidence

Clinical evidence for hydroxychloroquine sulfate primarily focuses on its established use as a Disease-Modifying Anti-Rheumatic Drug (DMARD) in autoimmune conditions, as well as investigations into its potential for other applications.


Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA)

Long-standing clinical research supports the use of hydroxychloroquine sulfate in managing SLE and RA. Studies indicate that, for patients with SLE, use is associated with a reduced risk of disease flares and cumulative organ damage over time. Research also explored potential non-immunomodulatory effects, such as cardiovascular protection and a reduction in thrombotic events, which may be relevant for patients with SLE.

In RA, the drug is studied as a treatment to help reduce joint pain and swelling. Clinical findings suggest that it may provide symptom relief and help prevent disease progression, particularly when used as part of a combination therapy regimen.


Investigation into Other Conditions

More recent clinical trials have investigated the use of hydroxychloroquine sulfate for conditions outside of its approved indications, including various viral infections. Large, randomized, placebo-controlled trials have largely concluded that the drug did not demonstrate clinical benefit in reducing the risk of hospitalization or death for patients with certain viral infections and is not generally recommended for this purpose outside of specific research settings.


Safety Monitoring in Research

Research continues to monitor the drug's safety profile, particularly concerning the rare risk of retinal toxicity associated primarily with long-term use and high cumulative doses. Ongoing studies emphasize the importance of dose calculation based on body weight and the necessity of regular ophthalmological screening for individuals on prolonged therapy.

Key Studies & References

  1. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Rheumatoid Arthritis
  2. Hydroxychloroquine Retinopathy: Risk Factors, Screening, and Management
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Hydroxychloroquine Sulfate Actavis (FAQ)


Q: Is Hydroxychloroquine Sulfate Actavis the exact same medicine as Plaquenil?

A: Plaquenil is a brand name for a medicine that contains the active ingredient hydroxychloroquine sulfate. Hydroxychloroquine Sulfate Actavis contains the same active ingredient. Official regulatory documents describe the drug's properties based on the active chemical compound, not the various trade names.

Q: Is Hydroxychloroquine Sulfate Actavis considered a steroid?

A: No. Official medical classifications describe Hydroxychloroquine Sulfate Actavis as a Disease-Modifying Anti-rheumatic Drug (DMARD) and an Antimalarial. It does not belong to the pharmacological class of steroid medicines.

Q: How is the anti-inflammatory effect of this drug generally described in medical terms?

A: The general role of the medicine is described as achieving an anti-inflammatory effect through immunomodulation. This means its function is achieved by altering the internal environment of certain immune cells, which helps to mitigate or change systemic immune responses in the body.

Q: What is the timeline described in research for when the treatment begins to show its full effect?

A: Official prescribing information notes that the action of the medicine is cumulative. This means the full therapeutic effect is not immediate and may require sustained use over a period of weeks to months to be achieved.

Q: How long can Hydroxychloroquine Sulfate Actavis stay in the body after the last dose?

A: The elimination process is noted to be lengthy. The regulatory label describes the elimination half-life as being approximately 40 days.

Q: Are changes in hair color or hair loss a common or rare side effect?

A: In official safety profiles, Alopecia (hair loss) and changes in skin pigmentation are classified as Uncommon side effects. This means they are reported in between 1/1000 and 1/100 patients.

Q: What kind of specialist typically prescribes and manages treatment with this drug?

A: Because this is a prescription-only medicine with specific uses, treatment is typically prescribed and managed by specialists. This most often includes a rheumatologist for chronic autoimmune conditions or an infectious disease physician for malaria treatment.

Q: How do official sources describe the process for monitoring potential heart problems (ECG)?

A: Official safety information notes that the drug carries a risk of serious cardiac events, including QTc prolongation (a change in the heart's electrical activity). This risk requires regular monitoring of the patient's heart function, which may include the use of an electrocardiogram (ECG).

Q: How is the safe daily dosage generally calculated or described in medical literature (e.g., mg/kg)?

A: Regulatory documents indicate that the chronic daily maintenance dose for long-term use should generally not exceed 6.5 mg/kg of ideal body weight. This calculation is a key measure used to minimize the long-term risk of developing retinal damage.

Q: Is it described as normal to not feel an immediate effect after starting the treatment?

A: Yes, official information indicates this is normal. Due to the drug’s mechanism involving slow accumulation in tissues, the therapeutic effect is inherently delayed. Patients should not expect to feel an immediate change after beginning treatment.

Q: Why is Hydroxychloroquine Sulfate Actavis sometimes used for conditions other than malaria?

A: Hydroxychloroquine Sulfate Actavis is officially approved for the treatment of certain chronic autoimmune conditions, in addition to malaria. These approved uses include Systemic Lupus Erythematosus (SLE) and Rheumatoid Arthritis (RA).

Q: Is it common to experience a metallic taste or changes in appetite while using this drug?

A: Official patient information lists loss of appetite and nausea as possible side effects. While the regulatory label does not specifically address a metallic taste, gastrointestinal side effects are commonly reported.

Q: Is there a known interaction between Hydroxychloroquine Sulfate Actavis and alcohol consumption?

A: The regulatory label does not list a formal, severe interaction with alcohol. However, official safety profiles contain general warnings about the drug’s potential for liver toxicity and common side effects like dizziness, which may be heightened by alcohol consumption.

Q: Can Hydroxychloroquine Sulfate Actavis affect a patient's sleep or cause vivid dreams?

A: Official safety profiles note that neuropsychiatric side effects are possible. These can include mood or mental changes, and in some instances, effects such as insomnia or, rarely, psychotic symptoms.

Q: Does Hydroxychloroquine Sulfate Actavis build up in certain tissues over time?

A: Yes. The medicine’s mechanism of action relies on its slow, steady accumulation in specific cells and tissues throughout the body. This accumulation is necessary for the drug to exert its primary functions.

Q: Is there information regarding the use of Hydroxychloroquine Sulfate Actavis in elderly patients?

A: Regulatory guidance emphasizes the need for long-term safety monitoring for all patients, which is especially relevant for older patients. This monitoring focuses on the rare, dose-dependent risk of retinal damage due to prolonged exposure.

Q: Are there any known interactions between this medicine and certain herbal supplements?

A: Regulatory-affiliated sources state there is not enough official information available to verify the safety profile of all herbal remedies and supplements when taken with this medicine, as they are generally not tested in formal drug interaction studies.

Q: What are the described signs that might indicate a cardiotoxicity concern with this drug?

A: Official patient information describes specific signs of cardiac concern that may be reported to a healthcare professional. These may include having a fast or irregular heartbeat, or experiencing lightheadedness, dizziness, or fainting.

Q: Do official documents describe any risk of muscle weakness (myopathy) with long-term use?

A: Official safety information notes muscle weakness as a possible side effect. Regulatory literature describes that long-term use is associated with a risk of myopathy, which refers to muscle toxicity.

Q: Why is the drug often taken with food or milk?

A: Regulatory instructions note that taking the medicine with a meal or a glass of milk may help minimize potential gastrointestinal upset, a commonly reported side effect.

Q: Can Hydroxychloroquine Sulfate Actavis affect a patient’s ability to drive or operate machinery?

A: Yes. Official warnings advise patients about the risk of impaired accommodation and blurring of vision. If these side effects occur, they may impact the ability to safely drive or operate heavy machinery.

Q: Does the drug have a warning related to neuropsychiatric side effects like confusion or hallucinations?

A: Yes. Official safety information notes the possible occurrence of mood or mental changes. In rare cases, more severe neuropsychiatric effects, such as confusion or hallucinations, have been documented.

Q: Are there different dose guidelines mentioned for use in pediatric versus adult patients?

A: Yes. Pediatric dosing for approved uses, such as malaria prophylaxis, is based on the child's actual body weight. These weight-based calculations are used to establish a safe maximum dose relevant to the child's body weight.

Q: Is there information about the drug’s effectiveness in areas with Chloroquine-resistant malaria?

A: Regulatory documents state that this medicine is not effective against chloroquine-resistant strains of Plasmodium species (the parasites that cause malaria). It is intended for use against susceptible strains.

Q: What are the documented reasons for stopping Hydroxychloroquine Sulfate Actavis treatment?

A: Regulatory documents outline conditions that may lead to the discontinuation of treatment. These include the development of retinal toxicity, signs of cardiotoxicity, or if the chronic condition shows no improvement after six months of treatment.

Q: Is it mentioned in official documents that the drug can be taken every other day?

A: Official administration guidelines specify that the dose for chronic conditions should be administered daily (as a single or divided dose) or, for malaria prophylaxis, once weekly. Alternate-day dosing is not specified in regulatory documentation.

Q: What is the overall goal of the required regular medical monitoring during therapy?

A: The primary purpose of required regular medical monitoring, such as eye and heart checks, is to allow for the early detection of potential adverse reactions. This ensures that the cumulative dosage remains within acceptable safety limits over time.

Advertisements

How should Hydroxychloroquine Sulfate Actavis be stored and disposed of?

Official Storage and Disposal Requirements

This medication must be stored according to strict regulatory specifications to maintain its effectiveness and ensure safety.

Requirement Type Official Instructions
Storage Temperature Store at Controlled Room Temperature (20 C to 25 C, allowing excursions between 15 C and 30 C).
Container & Environment Keep in a tight container in a cool, dry place.
Child Safety Keep out of the reach of children. Accidental ingestion can be fatal, making secure storage a critical safety measure.
Handling Do not crush the tablets.
Disposal Dispose of unused or expired product through an authorized drug take-back program. If no program is available, mix the tablets with an undesirable substance (e.g., dirt) and seal them in a plastic bag before placing them in the household trash, following the recommended method for non-flushable medications.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Hydroxychloroquine Sulfate Actavis found in:

A-Z Index: